These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 34531847)

  • 1. Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy.
    Khan M; Arooj S; Wang H
    Front Immunol; 2021; 12():651634. PubMed ID: 34531847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
    Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
    Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
    Picarda E; Ohaegbulam KC; Zang X
    Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New checkpoints in cancer immunotherapy.
    Ni L; Dong C
    Immunol Rev; 2017 Mar; 276(1):52-65. PubMed ID: 28258699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers.
    Mestiri S; El-Ella DMA; Fernandes Q; Bedhiafi T; Almoghrabi S; Akbar S; Inchakalody V; Assami L; Anwar S; Uddin S; Gul ARZ; Al-Muftah M; Merhi M; Raza A; Dermime S
    Biomed Pharmacother; 2024 Feb; 171():116095. PubMed ID: 38183744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7-H7 Is Inducible on T Cells to Regulate Their Immune Response and Serves as a Marker for Exhaustion.
    Luu K; Schwarz H; Lundqvist A
    Front Immunol; 2021; 12():682627. PubMed ID: 34140952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
    Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
    Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypical and potential functional characteristics of different immune cells expressing CD28H/B7-H5 and their relationship with cancer prognosis.
    Zhong C; Lang Q; Yu J; Wu S; Xu F; Tian Y
    Clin Exp Immunol; 2020 Apr; 200(1):12-21. PubMed ID: 31901178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
    D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
    Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.
    Nishizaki D; Kurzrock R; Miyashita H; Adashek JJ; Lee S; Nikanjam M; Eskander RN; Patel H; Botta GP; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S
    ESMO Open; 2024 Apr; 9(4):102942. PubMed ID: 38503143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting T cell costimulation in autoimmune disease.
    Stuart RW; Racke MK
    Expert Opin Ther Targets; 2002 Jun; 6(3):275-89. PubMed ID: 12223069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
    Dempke WCM; Fenchel K; Uciechowski P; Dale SP
    Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structures of Immune Checkpoints: An Overview on the CD28-B7 Family.
    Liu W; Zang X
    Adv Exp Med Biol; 2019; 1172():63-78. PubMed ID: 31628651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies.
    Pulanco MC; Madsen AT; Tanwar A; Corrigan DT; Zang X
    Cell Mol Immunol; 2023 Jul; 20(7):694-713. PubMed ID: 37069229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.
    Schildberg FA; Klein SR; Freeman GJ; Sharpe AH
    Immunity; 2016 May; 44(5):955-72. PubMed ID: 27192563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New B7 Family Checkpoints in Human Cancers.
    Ni L; Dong C
    Mol Cancer Ther; 2017 Jul; 16(7):1203-1211. PubMed ID: 28679835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
    Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
    J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the B7 family of co-stimulatory molecules: successes and challenges.
    Podojil JR; Miller SD
    BioDrugs; 2013 Feb; 27(1):1-13. PubMed ID: 23329394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.